Introduction {#s1}
============

RNA binding proteins (RNABPs) play critical roles in the brain to regulate neuronal development and activity, as underscored by the finding that dysregulation of RNABP function underlies a growing list of neurological disorders ([@bib46]; [@bib7]; [@bib64]). This connection was first highlighted by the use of autoantibodies present in the paraneoplastic neurologic disorders ([@bib12], [@bib9]; [@bib11], [@bib14]) to discover that NOVA and ELAVL/Hu are neuron-specific RNABPs ([@bib74]; [@bib5]; [@bib60]; [@bib40]; [@bib18]). The characterization of these proteins, as well as a number of subsequently described mammalian RNABPs, including NeuN/RBFOX3 ([@bib40]; [@bib18]) and brPTB/nPTB/PTBP2 ([@bib52]; [@bib63]), suggests that the brain, and neurons in particular, harbor unique sets of RNABPs to uniquely regulate RNA metabolism ([@bib10]).

NOVA proteins are among the best-studied mammalian tissue-specific RNABPs. Two paralogs, NOVA1 ([@bib5]) and NOVA2 ([@bib85]), are present in mammals, with largely indistinguishable biochemical properties but largely reciprocal expression within the central nervous system ([@bib10]). They bind to YCAY-rich elements ([@bib4]; [@bib35]; [@bib45]; [@bib80]) to regulate neuronal alternative splicing ([@bib63]; [@bib37]; [@bib16]; [@bib17]; [@bib81]; [@bib48]) and mRNA transport of some target RNAs ([@bib67]). NOVA-mediated RNA regulation is essential, as *Nova* DKO (*Nova1*^−/−^ and *Nova2*^−/−^) mice die immediately at birth ([@bib69]), although the range of NOVA actions is still being enumerated ([@bib90]). For example, NOVA, like many other splicing factors ([@bib31]), shuttles between the nucleus and cytoplasm ([@bib67]), reflecting the interesting but incompletely understood relationship between the regulation of RNA splicing, transport, stability, localization and translation ([@bib51]; [@bib31]; [@bib53]; [@bib13]).

Several well-defined RNA elements mediate RNA stability and localization, such as 3′ UTR adenine/uridine-rich (ARE) elements recognized by the Elavl family of RNABPs ([@bib43]; [@bib58]; [@bib62]; [@bib3]; [@bib41]) and the zipcode recognized by ZBP1 ([@bib6]). NOVA may play coordinate roles in the nucleus and cytoplasm, as HITS-CLIP studies have shown direct binding to introns and 3′ UTRs of *GlyRa2* and *Girk2* mRNA ([@bib67]), and evidence of splicing and a role for localization in each. However, the extent and means by which NOVA might mediate actions in both compartments remains uncertain.

Here we explore the relationship between nuclear and cytoplasmic functions of NOVA by undertaking HITS-CLIP ([@bib13]) on each fraction separately, and comparing results with microarray analysis of RNA in *Nova*-null mice. NOVA crosslinks to many transcripts in both nuclear/intronic and cytoplasmic/3′ UTR clusters, suggesting an ordered set of cis-actions on target RNAs. Surprisingly, however, among 229 transcripts showing significant steady-state changes, NOVA binding was primarily present in intronic rather than cytoplasmic elements. This led us to hypothesize and identify previously unannotated exons or alternative splicing patterns near these intronic elements that introduced premature termination codons (PTC) able to mediate nonsense-mediated mRNA decay (NMD). Thus HITS-CLIP reveals that NOVA regulates otherwise cryptic NMD exons in the nucleus to indirectly regulate steady-state mRNA levels in the cytoplasm. We put this finding in a physiologic context, showing that these exons encode synaptic proteins, they are regulated by seizure activity, and that Nova itself is important in epilepsy, as the protein shifts from the neuronal nucleus to cytoplasm shortly after seizure, and Nova haploinsufficient mice have spontaneous epilepsy. Together, these data suggest a role for Nova in maintaining homeostasis after seizure, in part through the regulation of cryptic NMD exons.

Results {#s2}
=======

Changes in steady-state transcript levels in NOVA DKO brain {#s2-1}
-----------------------------------------------------------

Previous CLIP experiments have identified NOVA binding sites near alternative exons and poly(A) sites ([@bib79]; [@bib81], [@bib80]; [@bib48]), but have not fully addressed whether NOVA might also regulate the steady-state level of some transcripts. To assess the degree to which NOVA might regulate this aspect of neuronal mRNA metabolism, we compared steady-state levels of total poly(A)+ mRNAs in four *Nova* WT and four *Nova1*^−/−^/*2*^−/−^ (double KO; DKO) brains from P0 littermates (DKO mice die shortly after birth) with Affymetrix exon arrays. A total of 229 genes showing significant changes (\|log~2~(WT/DKO)\|\>0.3; p \< 0.05, Student\'s t-test) were identified ([Figure 1A](#fig1){ref-type="fig"}). Interestingly, this data indicated that NOVA had a disproportionate action to increase (rather than decrease) steady state levels of brain transcripts. Specifically, 215 of the 229 transcripts showed significant decreases in the absence of NOVA (NOVA-dependent 'upregulation' of steady-state mRNA levels; [Figure 1A](#fig1){ref-type="fig"}). 22 showed a \>1.5-fold change, and 11 of these were validated experimentally by qRT-PCR ([Figure 1B](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Only 14 transcripts showed comparable NOVA-dependent mRNA suppression of steady-state levels (five showing a greater than 1.5-fold change), and these were validated experimentally ([Figure 1C](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}).10.7554/eLife.00178.003Figure 1.NOVA proteins up/down-regulate transcript levels.(**A**) Affymetrix exon arrays were interrogated with RNA from WT vs DKO E18.5 mouse whole brains, and normalized transcript intensities were plotted in log~2~ scale (log~2~(WT/DKO) \> 0.3 or −0.3 and p\<0.05). The X-axis indicates ranks of transcripts from the top and Y-axis is the measure of relative transcript levels (WT/DKO) in log~2~ scale. Blue bracket represents transcripts whose levels are increased in WT relative to DKO brain (NOVA-dependent 'upregulation' of steady-state mRNA levels), and the purple bracket represents down-regulated transcripts in WT relative to DKO (NOVA-dependent repression of steady-state mRNA levels). (**B**),(**C**) qRT-PCR data of representative NOVA regulated transcripts. Y-axis represents the mRNA levels in which WT is normalized to 1.0. Data is from three biologic replicates (three animals) and three technical replicates (nine reactions per point); error bars represent standard deviation. For each point p\<0.001; see [Table 1](#tbl1){ref-type="table"} for additional data. NOVA up-regulated transcripts in WT versus DKO (**B**; corresponding to blue bracket in Figure 1A) and NOVA down-regulated transcripts (**C**; corresponding to purple bracket in Figure 1A) are shown. (**D**) Immunoblot analysis of NOVA distribution in nuclear and cytoplasmic fractions from mouse brain irradiated by UV. Each lane represents the different brain extracts as biological replicates. HSP90 is used as a cytoplasmic marker, and hnRNP-C1/C2 as a nuclear marker. The NOVA2 antibody detects both large and small NOVA2 isoforms ([@bib85]). (**E**) Breakdown of BC = 4 clusters for nuclear and cytoplasmic Nova HITS-CLIP. Downstream 10K clusters are enriched in unannotated 3′ UTRs ([@bib48]); see also [Table 2](#tbl2){ref-type="table"}. (**F**) Distribution of BC = 4 clusters by peak height for both nuclear and cytoplasmic HITS-CLIP; more stringent cytoplasmic clusters show enrichment in 3′ UTR. (**G**) Distribution of CLIP tags (intronic, red; 3′ UTR, blue) from the list of NOVA up-regulated RNAs. Each point on the X-axis represents a Nova-dependent gene (in arbitrary order) and Y-axis represents the percentage of intronic/3′ UTR tags for transcripts with total tags \>5.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.003](10.7554/eLife.00178.003)10.7554/eLife.00178.004Figure 1---figure supplement 1.Nova CLIP results.Nuclear (Nuc, blue; upper) and cytoplasmic (Cyt, red; lower) HITS-CLIP tags are shown. All unique tags from nuclear and cytoplasmic HITS-CLIP clusters were plotted onto the whole genome and showed a relatively low correlation (R^2^ = 0.32). By comparison, two independent cytoplasmic HITS-CLIP tags showed higher R^2^ values (0.765; data not shown). (**B**) BC4 clusters were grouped according to each gene, and CLIP tags from these clusters were summed up gene-by-gene for each individual experiment, to obtain the total number of BC4 tags for each gene. The first plot (Cyt total vs Nuc total) shows the correlation (R^2^ = 0.36) between the total number of nuclear CLIP tags per gene and the total number of cytoplasmic tags per gene; each point represents a gene. The other two plots are similar but the correlations were calculated using two Nuc CLIP experiments or two Cyt CLIP experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.004](10.7554/eLife.00178.004)10.7554/eLife.00178.005Figure 1---figure supplement 2.Correlations: analysis of Nova CLIP results.NOVA HITS-CLIP BC4 clusters were grouped according to each gene, and CLIP tags from these clusters were summed up gene-by-gene for each individual experiment, to obtain the total number of BC4 tags for each gene. The first plot (Cyt total vs Nuc total) shows the correlation (R^2^ = 0.36) between the total number of nuclear CLIP tags per gene and the total number of cytoplasmic tags per gene; each point represents a gene. The other two plots are similar but the correlations were calculated using two Nuc CLIP experiments or two Cyt CLIP experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.005](10.7554/eLife.00178.005)10.7554/eLife.00178.006Table 1.Validation data for transcripts showing Nova-dependent changes in steady-state mRNA levels**DOI:** [http://dx.doi.org/10.7554/eLife.00178.006](10.7554/eLife.00178.006)qRT-PCR foldMicroarray-predicted foldp-valueGeneTranscripts with larger predicted fold changes3.85 ± 0.843.39\<0.001**Dlg3** (Sap102)3.79 ± 0.292.73\<0.001**Dzip1**2.40 ± 0.432.25\<0.001Dtd13.64 ± 0.392.23\<0.001Rasgrp22.42 ± 0.151.97\<0.001**Slc4a3**1.74 ± 0.281.81\<0.001**Slc4a10**2.06 ± 0.31.72\<0.001Cacna2d31.73 ± 0.141.71\<0.001**Ahi1**1.90 ± 0.121.68\<0.001**Rasgrf1**1.83 ± 0.181.67\<0.001Slc1a61.53 ± 0.131.67\<0.001Lynx10.50 ± 0.070.68\<0.001**Cdk5rap2**0.40 ± 0.020.54\<0.001**Stx2**(syntaxin 2)0.30 ± 0.040.45\<0.001Cpne3(copine III)0.33 ± 0.070.34\<0.001**Scn9a**Transcripts with smaller predicted fold changes1.98 ± 0.161.48\<0.001Syt21.41 ± 0.11.47\<0.001**Actl6b**1.74 ± 0.071.40\<0.001Gria31.56 ± 0.091.30\<0.001Syngr3\*1.53 ± 0.131.29\<0.001Glrb\*1.33 ± 0.201.25\<0.001Gabbr1\*0.69 ± 0.070.77\<0.001**Plekha5**[^1]

These observations do not indicate whether NOVA acts directly or indirectly on these 229 transcripts to regulate their levels. HITS-CLIP has proven to be a reliable means of defining sites of direct functional RNA--protein interactions ([@bib47]). Analysis of prior CLIP data ([@bib48]; [@bib90]) demonstrated that many of the 229 transcripts showing NOVA-dependent changes in level had CLIP tags when whole brain extracts were crosslinked (see also below). Such changes could result from nuclear and/or cytoplasmic actions, and we have previously found evidence that NOVA may act in both compartments ([@bib67]). Therefore, we undertook a systematic comparison of NOVA binding in each compartment.

Nuclear and cytoplasmic NOVA HITS-CLIP {#s2-2}
--------------------------------------

To define NOVA-RNA interactions in the nucleus and cytoplasm separately, we crosslinked mouse brain cortex, 'freezing' RNA--protein complexes for analysis, and then subfractionated tissue into nuclear and cytoplasmic fractions. To assess the integrity of this fractionation, we performed immunoblot analysis with markers known to be specific for each fraction and antibodies to NOVA, demonstrating that each fraction was \>90% pure, and that ∼60% of NOVA was nuclear and 40% cytoplasmic ([Figure 1D](#fig1){ref-type="fig"}, consistent with and detailed in a previous study ([@bib67])). While this fractionation scheme (based on salt extraction) gave a relatively clean separation between each compartment, we cannot exclude the possibility that some NOVA protein was not extracted from each compartment under these conditions. Nonetheless, these data suggested that highly enriched NOVA-RNA complexes present in subcellular compartments could be purified and analyzed.

We examined NOVA RNA binding maps to nuclear and cytoplasmic RNAs by analyzing HITS-CLIP results from each fraction ([Figure 1E](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; see also [Table 2](#tbl2){ref-type="table"}). We defined NOVA CLIP tag clusters by grouping overlapping RNA tags identified in multiple biologic replicates (biologic complexity (BC) \> 2) ([@bib48]) from four independent animals. These clusters were classified according to their locations within protein-coding transcripts, using annotations from cDNA/EST data and RefSeq and UCSC known genes ([@bib90]). By focusing on CLIP tags in robust clusters (BC = 4, peak height (PH) ≥ 4), we observed that nuclear HITS-CLIP tags were enriched in introns (90%) and cytoplasmic HITS-CLIP tags in 3′ UTR (63%, including ∼13% within 10 kb downstream of annotated transcripts; [Figure 1F](#fig1){ref-type="fig"}; see ([@bib48])). NOVA cytoplasmic CLIP data also contained a significant number of intronic clusters, but many of these were derived from abundant non-coding RNA species, such as ribosomal RNAs (also evident in nuclear CLIP data). After we reanalyzed the clusters with repetitive sequences excluded, only 17% clusters were located in introns ([Figure 1F](#fig1){ref-type="fig"}). In addition, when we analyzed the distribution of clusters as a function of peak height (PH), we identified a large proportion of intronic clusters in nuclear CLIP data, while less than 5% of NOVA cytoplasmic CLIP tag clusters were intronic (at PH 12--14).10.7554/eLife.00178.007Table 2.Summary of CLIP tag mapping data**DOI:** [http://dx.doi.org/10.7554/eLife.00178.007](10.7554/eLife.00178.007)SampleTag totalTag mappableTag uniqueNuclear 11,504,3451,031,115429,527Nuclear 24,984,9973,161,194363,771Nuclear 37,184,0663,944,912214,982Nuclear 46,656,6283,144,744325,507Nuclear sum1,333,787Cytoplasm 11,454,697975,22289,463Cytoplasm 24,751,3312,780,17337,027Cytoplasm 33,653,6002,005,20236,228Cytoplasm 43,813,9602,382,94639,145Cytoplasmic sum201,863

The proportion of apparent cytoplasmic NOVA binding sites in introns was nonetheless an unexpectedly high number, prompting us to repeat the cytoplasmic purification with an independent method (based upon differential centrifugation; data not shown) and then repeat HITS-CLIP analysis on mouse brain. This experiment independently confirmed the presence and position of NOVA2 cytoplasmic (R^2^ = 0.77) and nuclear (R^2^ = 0.77) CLIP tags between experiments. We have not studied the function of the small numbers of reproducible NOVA 'cytoplasmic' intronic clusters further, which most likely reflect remaining impurity of the cell fractionation, but could also reflect other processes, including NOVA binding to non-coding RNAs, stable processed introns, or unspliced transcripts. Taken together, our data suggest that NOVA binds predominantly to intronic elements in pre-mRNA in the nucleus and mature mRNA elements in the cytoplasm, but may have an unexpected role in binding intronic non-coding RNA elements in the cytoplasm as well.

We previously identified RNA transcripts bound by NOVA in the nucleus that also co-localize with (*GlyRa2*) or are localized by (*Girk2*) NOVA in neuronal processes ([@bib67]), prompting us to compare the NOVA nuclear and cytoplasmic binding maps. We first compared the frequency and extent to which cytoplasmic NOVA clusters were also present in the same location in nuclear CLIP. There was a significant albeit small correlation between cytoplasmic and nuclear HITS-CLIP tags (R^2^ = 0.32, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) and robust clusters (BC = 4; R^2^ = 0.36, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Moreover, when we relaxed the stringency of the nuclear clusters, we found that in most transcripts with robust cytoplasmic clusters, NOVA was already bound to those clusters in the nucleus. Among 504 transcripts with robust cytoplasmic clusters (BC ≥ 4, PH \> 10), 235 had robust nuclear clusters (BC ≥ 4, PH \> 10), and an additional 251 (46.6%) had weaker nuclear clusters. There were 18 unique cytoplasmic clusters (i.e. clusters not present in nuclear CLIP, but in transcripts which nonetheless had nuclear clusters in other locations), suggesting the possibility of a reassortment of NOVA binding sites in cis on individual transcripts; such a mechanism might allow nuclear and cytoplasmic functions like RNA localization or RNA stability to be linked (see [@bib67]).

We analyzed the relationship between NOVA cytoplasmic and nuclear binding in transcripts whose levels are NOVA-dependent. One common mechanism by which transcript steady-state levels are regulated is through actions on stability elements within the 3′ UTR, either through the actions of miRNAs ([@bib20]) or through RNABP-RNA regulatory interactions via actions on conserved elements such as ARE sequences ([@bib3]; [@bib84]; [@bib39]). Surprisingly however, the distribution of NOVA CLIP tags within NOVA-regulated transcripts (specifically, in the 149 of 229 transcripts harboring ≥5 CLIP tags) revealed that the majority of NOVA CLIP tags (∼76%) were not present on the 3′ UTRs of NOVA-regulated transcripts. Instead the predominant location of NOVA CLIP tags on these transcripts was intronic ([Figure 1G](#fig1){ref-type="fig"}), suggesting the possibility that NOVA action on pre-mRNA might be linked to steady-state levels of NOVA target mRNAs.

*Dlg3 (SAP102)* mRNA and protein levels are reduced in the absence of NOVA {#s2-3}
--------------------------------------------------------------------------

To address the mechanism by which NOVA regulates mRNA steady-state levels, we analyzed individual targets in more detail. The transcript encoding *Dlg3* (*Sap102*) showed the most significant NOVA-dependent upregulation (i.e. the largest decrease in steady state levels in NOVA DKO brain) in exon arrays ([Figure 1B,C](#fig1){ref-type="fig"}), which was confirmed in qRT-PCR studies ([Table 1](#tbl1){ref-type="table"}). The *Dlg3* transcript had a large number of NOVA CLIP tags ([Figure 2A](#fig2){ref-type="fig"}), suggesting that it might be both directly bound and regulated by NOVA. Consistent with this possibility, we found a nearly 10-fold reduction in *Dlg3* mRNA in NOVA DKO brain RNA samples by Northern blot analysis using two different probes and semi-quantitative RT-PCR ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), with intermediate changes seen in single NOVA1 or NOVA2 KO mice (data not shown).10.7554/eLife.00178.008Figure 2.NOVA regulates the expression of *Dlg3* mRNA and protein.(**A**) Location of NOVA cytoplasmic and nuclear CLIP tags in chromosome X:96591589-99424482. Red and purple colors represent cytoplasmic CLIP tags and green and blue colors represent nuclear CLIP tags. The location of *Dlg3* is boxed in black and magnified in the lower box (chromosomeX:98002207-98013864). This higher magnification illustrates the position of *Dlg3* constitutive (yellow), alternative (colored) exons and 3′ UTR (brown) relative to CLIP tags, YCAY elements, and sequence conservation across species. More cytoplasmic tags were evident in the 3′ UTR and more nuclear tags in introns. Clusters of CLIP tags can be seen to overlap with the location of clusters of YCAY sequences (in grey) as well as bioinformatically predicated clusters of YCAY elements (in blue; see [@bib90]). (**B**) Northern blot analysis of *Dlg3* mRNA from three biologic replicates of WT or Nova KO brain mRNA. Equal amount of RNA was loaded (see [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Quantitation of relative RNA intensity (WT/DKO) was plotted as a relative ratio of *Dlg3* mRNA in WT, N1 KO, N2 KO or DKO brain as indicated; error bars represent standard deviation (p\<0.05); about 90% of *Dlg3* mRNA is absent in DKO brain. (**C**) Immunoblot analysis of DLG3 in WT vs DKO. Protein extracts from the four different WT or DKO mouse brains (as indicated; E18.5) were assessed, and γ-TUBULIN was used as a normalizing control. Quantitation of protein intensity is indicated in graph to the right, plotted as relative ratio of DLG3 in WT/DKO, indicate that ∼90% of DLG3 protein is absent in DKO brain; error bars represent standard deviation (p\<0.05). (**D**) Immunofluorescence detection of DLG3 (red), NOVA (blue) and Neurofilament (NF) (green) proteins on WT/DKO mixed primary mouse neuronal cultures. DAPI and neurofilament stained all neuronal nuclei and processes, respectively, while NOVA staining differentiates WT and DKO neurons. The DLG3 signal was markedly reduced in DKO neurons. Scale bar: 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.008](10.7554/eLife.00178.008)10.7554/eLife.00178.009Figure 2---figure supplement 1.*Dlg3* mRNA isoforms in Nova KO brain.Northern blot analysis of *Dlg3* mRNA in WT and *Nova* DKO brain. (**A**) *Gapdh* probe was used as a normalizing control. Panel to right: Quantitation of relative RNA intensity (WT/DKO) was plotted as a relative ratio of *Dlg3* mRNA/GAPDH in WT/DKO; error bars represent standard deviation (p\<0.05). About 75% was reduced in DKO.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.009](10.7554/eLife.00178.009)10.7554/eLife.00178.010Figure 2---figure supplement 2.Northern blot analysis of *Dlg3* mRNA in Nova KO brain-reproducibility and control.Reproduction of Northern blot for *Dlg3* mRNA presented in [Figure 2B](#fig2){ref-type="fig"}, but also showing loading control below (Ethidium bromide (EtBr) stain of the gel), demonstrating equal loading of all RNAs.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.010](10.7554/eLife.00178.010)

To assess whether these changes in mRNA levels led to corresponding changes in DLG3 protein levels, we analyzed protein extracts from NOVA WT vs DKO brain. Western blots demonstrated that DLG3 protein levels were severely reduced (∼90% reduction; [Figure 2C](#fig2){ref-type="fig"}) in DKO brain, closely reflecting the reduction in *Dlg3* mRNA. We also examined DLG3 protein by immunofluorescence microscopy using anti-DLG3 antibodies. We co-cultured WT/DKO neurons together and stained for NOVA protein to distinguish WT from DKO neurons, using Neurofilament-M (NF-M) immunoreactivity as a positive control to stain all neurons. These experiments clearly showed that NOVA DKO neurons had very little DLG3 signal ([Figure 2D](#fig2){ref-type="fig"}). Taken together, these data demonstrate that the absence of NOVA protein in neurons is associated with a drastic reduction in *Dlg3* mRNA levels and a concomitant reduction in DLG3 protein levels.

To address whether NOVA protein might directly regulate *Dlg3* mRNA levels, we examined the specific locations of NOVA HITS CLIP tags along the *Dlg3* transcript ([Figure 2A](#fig2){ref-type="fig"}). NOVA binding sites were present in both the 3′ UTR and introns, and in both locations these sites harbored NOVA binding elements (clusters of the sequence YCAY; ([@bib90])). To assay the functional outcome of NOVA binding to the 3′ UTR elements, we generated a construct encoding a destabilized d1EGFP fused to either a 214 nt fragment (NOVA binding clusters in 3′ UTR shown in [Figure 2A](#fig2){ref-type="fig"}) from the wild-type *Dlg3* 3′ UTR or a mutant fragment which would disrupt NOVA binding (YCAY-\>YAAY; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). 24 hr after transfection of these constructs into Neuro2a (N2a) neuroblastoma cells, actinomycin D was added for 5 hr in order to block transcription, and *Dlg3* mRNA levels were followed by qRT-PCR ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). These data revealed a relatively small but clear decrease in d1EGFP mRNA containing mutant YAAY NOVA binding sites (∼50% reduction) compared to transcripts harboring WT YCAY elements, indicating that NOVA binding to the 3′ UTR had a small effect on *Dlg3* steady state levels. However, this interaction did not appear to be sufficient to explain the large effect NOVA had on transcript (see [Table 1](#tbl1){ref-type="table"}) and protein levels in neurons, prompting us to examine whether additional NOVA actions on *Dlg3* intronic elements contributed to effects on steady-state RNA levels.

*Dlg3* mRNA level is reduced in NOVA DKO through actions on cryptic NMD transcripts {#s2-4}
-----------------------------------------------------------------------------------

The NOVA nuclear HITS-CLIP results demonstrated NOVA intronic and 3′ UTR binding sites that were present only in nuclear and cytoplasmic HITS-CLIP, respectively, ([Figure 2A](#fig2){ref-type="fig"}), suggesting a hierarchy of NOVA action. To explore whether NOVA intronic binding sites might relate to an action on *Dlg3* steady-state mRNA levels, we empirically searched for cryptic alternative splicing events in regions neighboring the largest intronic HITS-CLIP clusters, given previous observations indicating that NOVA intronic clusters predict alternative splicing outcomes ([@bib17]; [@bib77]; [@bib48]; [@bib90]). RT-PCR was performed in WT vs. NOVA DKO brain RNA using primers bounding introns harboring NOVA HITS-CLIP clusters (exons 14 (E14) and E18 in [Figure 2A](#fig2){ref-type="fig"}). In WT mouse brain two isoforms were detected and sequenced, and these were found to correspond to known alternative spliced isoforms, harboring what we refer to as E16, with or without E17, and a trace amount of a larger isoform. Remarkably, RT-PCR analysis of NOVA DKO mouse brain RNA revealed a marked increase of this larger isoform, and the presence of a previously unknown fourth, even larger form. Sequence analysis revealed the latter two isoforms correspond to the inclusion of an exon, E15, just downstream of the main Nova nuclear CLIP cluster, and a new combination of exons undetectable in WT brain, incorporating both E15 and E16 (as well as E17; termed Dlg3.15-16-17). E16 also has a second upstream intronic CLIP cluster, suggesting that the Nova binding sites upstream of E15 and E16 could normally act to suppress their dual inclusion, consistent with their inclusion in the DKO brain and with the Nova position-dependent splicing map ([@bib48]; [@bib47]).

Interestingly, the previously unknown Dlg3 isoform (Dlg3.15-16-17) encoded a transcript harboring a PTC, formed by the inclusion of both E15 and E16 (see [Figure 3A](#fig3){ref-type="fig"}). This suggested that the marked reduction in DLG3 protein levels might relate to nonsense-mediated mRNA decay (NMD), an mRNA surveillance mechanism in which transcripts containing PTCs are recognized and degraded in association with early rounds of translation ([@bib72]).10.7554/eLife.00178.011Figure 3.*Dlg3* mRNA is decreased through inclusion of cryptic NMD exons in the absence of NOVA.(**A**) RT-PCR and sequence analysis ([Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"}) showed four *Dlg3* isoforms which have different combinations of alternatively spliced exons. The lower two PCR products (WT1 and WT2), respectively, harbor alternative exon 16 (E16) with or without E17, and both encode in-frame protein variants. The upper two PCR products, evident in DKO brain (DKO3 and DKO4), include E15, with or without E16, and include E17. The DKO4 isoform was not annotated in Refseq, and the combination of E15 and E16 led to a frameshift and inclusion of a premature stop codon (TAA) in E16, as indicated in the schematic (also leading us to color E16 red in [Figure 2A](#fig2){ref-type="fig"}). The 15--17 containing product does not make a premature stop codon. (**B**) After 6 DIV primary mouse neuronal cultures were treated with 100 μg/ml emetine for 10 hr, RNA was harvested from triplicate samples and analyzed by RT-PCR. Emetine treatment had no effect cell viability nor on isoforms produced in WT cells, but led to accumulation of the NMD isoform DKO4 in Nova DKO neurons. Spliced isoforms are indicated. (**C**) siRNA to Upf1 was transfected into DKO mouse primary cells, and after 24 hr, DLG3 (red) and UPF1 (green) protein was detected by immunofluorescence microscopy. Arrows indicate cells that have relatively high UPF1 levels; these cells have low DLG3 levels. In contrast, cells transfected with Upf1 siRNA (asterisks) had markedly reduced Upf1 levels and had increased (rescued) DLG3 levels. Upper and lower rows represent independent experiments. Scale bar: 10 µm. (**D**) Quantitation of DLG3 signal in Upf1 positive and Upf1 knockdown cells in (**C**). Signal intensity was normalized to the signal in Upf1 positive cells. Error bar represents standard deviation (p\<0.05).**DOI:** [http://dx.doi.org/10.7554/eLife.00178.011](10.7554/eLife.00178.011)10.7554/eLife.00178.012Figure 3---source data 1.Sequence of RT-PCR products (from [Figures 3 and 5](#fig3 fig5){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.00178.012](10.7554/eLife.00178.012)10.7554/eLife.00178.013Figure 3---figure supplement 1.Reporter construct design for NOVA 3′ UTR actions.Schematic of a reporter encoding destabilized d1EGFP and the 3′ UTR YCAY element of NOVA\'s target RNA. An identical construct in which the YCAY sequences were mutated to YAAY was also made.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.013](10.7554/eLife.00178.013)10.7554/eLife.00178.014Figure 3---figure supplement 2.NOVA increases the stability of some RNAs through binding to 3′ UTR YCAY elements.qRT-PCR was used to quantitate d1EGFP mRNA after transfection of various constructs (Syngr3 \[synaptogyrin 3\], Glrb \[Glycine receptor b\], *Dlg3* and Syt2 \[Synaptotagmin 2\]). Quantitation of steady state changes in RNA levels (YAAY relative to YCAY constructs) were 50%, 25%, 65%, 48%, respectively, for Syngr3, Glrb, *Dlg3* and Syt2. The Y-axis represents the relative mRNA levels (YCAY/YAAY). Interestingly, for *Dlg3*, a small 3′ UTR construct (115 nt) did not show any change, while a longer construct (214 nt) did, even though both harbored the YCAY element, suggesting that additional elements or RNA structures may be important for binding of NOVA to this 3′ UTR YCAY element. Asterisks indicate p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.014](10.7554/eLife.00178.014)

To assess whether NOVA acted on the Dlg3.15-16-17 through NMD, we examined the effect of blocking NMD on NOVA-dependent *Dlg3* splicing using multiple approaches ([@bib54]). First, we added emetine, a translational inhibitor, into primary neuronal cultures of neurons obtained from WT or NOVA DKO mouse brain, since a pioneering round of translation is necessary to activate the NMD pathway ([@bib59]; [@bib72]). After emetine treatment for 10 hr, RNA was isolated and *Dlg3* splicing was assayed by RT-PCR. In WT neurons, emetine had no effect on *Dlg3* splicing. However, in the absence of NOVA, emetine induced a dramatic increase in the NMD isoform Dlg3.15-16-17, and total *Dlg3* mRNA levels increased by 3.5-fold ([Figure 3B](#fig3){ref-type="fig"}). This result establishes a link between the ability to detect NOVA-dependent splicing of Dlg3.15-16-17 and active translation, suggesting that this isoform is normally suppressed coordinately both by NOVA and NMD.

To more directly assess whether *Dlg3.15-16-17* is regulated by NMD, we knocked down a core component of the NMD pathway, Upf1 ([@bib57]), with Upf1 siRNA. We first established that Upf1 siRNA was able to reduce UPF1 protein (by ∼90%) in N2a cells ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We then transfected Upf1 siRNA into cultured primary neurons to readdress the possibility of coordinate regulation by NOVA and NMD. In primary neuronal cultures, transfection efficiency was lower, such that only about half of the cells were transfected, and we detected a concomitant ∼50% decrease in *Upf1* transcript in qRT-PCR analysis ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Hence to directly assess the effects of *Upf1* knock-down on a per-cell basis, we transfected *Upf1* siRNA into WT or DKO primary neuronal cultures, and monitored DLG3 and UPF1 protein levels in individual cells by immunofluorescence microscopy. These experiments revealed a reciprocal relationship between DLG3 protein and UPF1 protein levels in NOVA DKO neurons. DLG3 protein level was very low in untransfected DKO neurons that expressed UPF1 protein (see [Figures 2D and 3C](#fig2 fig3){ref-type="fig"}), whereas cells in which UPF1 signals were markedly reduced by *Upf1* siRNA exhibited a markedly increased DLG3 signal. We interpret these results to indicate that when the NMD pathway was inhibited by Upf1 knock-down, mis-spliced *Dlg3.15-16-17* mRNA led to accumulation of DLG3 protein that escape NMD degradation and accumulate at the protein level. This may have included truncated isoforms, as these experiments used an antibody against a Dlg3 N-terminal epitope; (see 'Materials and methods'). More generally, these results demonstrate that NOVA regulation of a cryptic alternatively spliced exon is necessary to prevent NMD-mediated suppression of Dlg3 expression in the brain, and this can act in concert with 3′ UTR binding to maintain Dlg3 expression.

*Scn9a* mRNA and protein level increases in NOVA DKO through NOVA-dependent splicing-coupled NMD {#s2-5}
------------------------------------------------------------------------------------------------

We next explored an example of the less common converse situation, in which microarray analysis revealed NOVA-dependent decreases in steady-state mRNA levels. We examined *Scn9a* mRNA, which showed the largest increase of 2.9-fold in NOVA DKO brain in the microarray data. We first independently validated this data, demonstrating that *Scn9a* mRNA level increased in NOVA DKO RNA by qRT-PCR ([Table 1](#tbl1){ref-type="table"}). We then determined whether the effects of NOVA on steady state *Scn9a* mRNA were reflected at the protein level. Western blot analysis revealed a marked reduction (∼12-fold) of SCN9a protein in NOVA DKO brain ([Figure 4A,B](#fig4){ref-type="fig"}), indicating that NOVA normally acts to suppress SCN9a expression at both the RNA and protein levels in the brain.10.7554/eLife.00178.015Figure 4.NOVA and NMD-mediated regulation of *Scn9a* mRNA and protein.(**A**) Immunoblot analysis of SCN9a in WT vs DKO. Proteins extracts from WT (lane 1--3) vs DKO (lane 4--6) were loaded. γ-Tubulin was used as a normalizing control. (**B**) Quantitation of relative protein intensity (WT/DKO). The results were plotted as a relative ratio of SCN9a in WT/DKO; error bars represent standard deviation (p\<0.05). About 90% signal was reduced in WT. (**C**) RT-PCR from WT and DKO (three biologic replicates) shows NOVA-dependent splicing of *Scn9a*. WT brains express two alternative splicing isoforms (lanes 1--3), while DKO brains express only the smaller isoform (lanes 4--6). A (−) RT control is indicated; primers are given in [Supplementary file 2](#SD3-data){ref-type="supplementary-material"}. (**D**) Sequence analysis and map of the spliced isoforms from Figure 4C showed that the larger band corresponds to a transcript in which an exon (17a) was included, introducing a premature stop codon. In the sequence shown, exon 17a is highlighted in black, and the TAA premature stop codon is indicated in red. (**E**) Six DIV WT primary mouse neuronal cultures were treated with emetine, as indicated, for 10 hr and RT-PCR was performed. The NMD exon was increased after emetine treatment. (**F**) siRNA to *Upf1* or a non-targeting siRNA were transfected in WT mouse primary cells, and RT-PCR was performed with the same primers used in Figures 4C,E. The intensity of the NMD exon was increased specifically after *Upf1* siRNA treatment.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.015](10.7554/eLife.00178.015)10.7554/eLife.00178.016Figure 4---figure supplement 1.N2A cells: Upf1 siRNA efficiently reduces endogenous UPF1 protein levels.siRNA targeting *Upf1* was transfected into N2a cells and immunoblot analysis of UPF1 protein was performed. Results from two independent experiments are shown. siRNA to *Upf1* showed the significant reduction of UPF1 protein expression compared with a control untargeting siRNA. γ-Tubulin was used as a normalization control.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.016](10.7554/eLife.00178.016)10.7554/eLife.00178.017Figure 4---figure supplement 2.Primary neurons: Upf1 siRNA reduces endogenous UPF1 protein levels.qRT-PCR quantitation of relative *Upf1* mRNA levels in primary neurons with or without treatment with *Upf1* siRNA. Error bars represents standard error of the mean; n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.017](10.7554/eLife.00178.017)

When we examined *Scn9a* transcripts for NOVA binding in HITS-CLIP data, we found no 3′ UTR tag clusters. Given that NOVA regulated *Dlg3* mRNA through repression of the NMD pathway, we explored whether an action of NOVA on NMD might also explain its effect on *Scn9a* mRNA steady-state levels. We found that *Scn9a* did harbor a major tag cluster in an intron upstream of a previously uncharacterized but conserved exon ([Figure 4D](#fig4){ref-type="fig"}; based on one sequenced transcript; NCBI accession: AM905322). Empirically, we assayed mRNA expression in this region from WT vs DKO brain by RT-PCR ([Figure 4C](#fig4){ref-type="fig"}). Interestingly, in WT brain the *Scn9a* transcript had two isoforms, but in NOVA DKO brain the larger isoform was lost. Sequence analysis demonstrated that this larger isoform corresponded to an alternative exon 17, termed E17a, that was not represented in RefSeq (as it corresponded to a partial mRNA sequence only), and that E17a harbored a PTC ([Figure 4D](#fig4){ref-type="fig"}). Again, this data was consistent with the upstream position of the NOVA CLIP tag clusters relative to E17a ([Figure 4C](#fig4){ref-type="fig"}) predicting ([@bib48]; [@bib47]) that NOVA would normally act to suppress E17a inclusion.

These findings suggested that in the WT brain, Nova-mediated inclusion of *Scn9a* E17a was normally used to produce transcripts that are likely degraded by NMD, and that E17a exclusion in the absence of NOVA activity could lead to an increase in steady state mRNA and protein level. To test the role of NMD in NOVA-mediated regulation of *Scn9a* levels, we applied emetine to primary WT neurons to inhibit translation and NMD. After 10 hr, RT-PCR was performed using primers bounding E17a. Emetine treatment increased the levels of E17a-included *Scn9a* transcripts compared to non-treated cells (∼75% increase; [Figure 4E](#fig4){ref-type="fig"}). In addition, we transfected Upf1 siRNA into WT primary neuronal cultures, and observed an increase in *Scn9a* E17a containing mRNA after siRNA KD ([Figure 4F](#fig4){ref-type="fig"}). Taken together, these observations indicate that *Scn9a* mRNA and consequently protein is held in balance by a NOVA-regulated NMD pathway.

NOVA-dependent regulation through NMD {#s2-6}
-------------------------------------

To find additional NOVA-dependent NMD target mRNAs, we searched HITS-CLIP data and exon array data for target RNAs that had unexplained NOVA intronic CLIP tags ('orphan clusters') and whose steady-state level was NOVA-dependent. Since not all alternative exons and splicing patterns are fully annotated, particularly those associated with NMD, we empirically searched for cryptic exons in introns that had robust NOVA orphan clusters in nuclear CLIP experiments. Among 15 transcripts showing significant NOVA-dependent changes ([Table 1](#tbl1){ref-type="table"}), 11 transcripts harbored robust NOVA intronic CLIP tag clusters. We designed RT-PCR primers in exons bounding these orphan intronic NOVA binding sites and assessed whether cryptic NOVA-dependent NMD exons could be identified. We identified and sequenced cryptic NOVA-regulated exons, evident only in NOVA DKO brain RNA, in 9 of these 11 transcripts, as well as in an additional 2 transcripts (see [Table 1](#tbl1){ref-type="table"}, and [Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"}), and found PTCs in each ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In 7 transcripts splicing was consistent with NOVA-dependent inclusion of an NMD exon, such that these exons were absent in NOVA DKO brain, and in each case these correlated with increased steady-state mRNA levels in NOVA DKO brain. Conversely, in 4 transcripts splicing of these cryptic exons was consistent with NOVA-dependent suppression of an NMD exon and decreased steady-state levels in NOVA DKO brain.

To assess whether these transcripts were indeed regulated through NMD, we added emetine to primary neuronal cultures and examined the steady-state expression of the putative NMD-exons. After emetine treatment for 10 hr, qRT-PCR was performed on five transcripts in WT and DKO neurons. When we plotted normalized fold changes on a log~2~ scale, the results demonstrated that *Dlg3*, Rasgrf1 and Slc4a3 were degraded by NMD in DKO relative to WT mice, while Stx2 and *Scn9a* degradation by NMD in WT mice was alleviated in NOVA DKO animals ([Figure 5B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Taken together, these data indicate the extensive use of NOVA in steady-state neurons to inhibit cryptic NMD exons, and, to a lesser degree, mediate inclusion of NMD exons, as a means to maintain or reduce, respectively, the steady-state levels of neuronal transcripts and proteins.10.7554/eLife.00178.018Figure 5.NOVA regulates cryptic NMD exons and transcript levels.(**A**) Analysis of alternative spliced isoforms in transcripts chosen solely on exon array data showing NOVA-dependent steady-state mRNA changes and robust HITS-CLIP clusters in introns. Transcripts were then screened for the presence of cryptic NMD exons by RT-PCR using primers in exons bounding the intronic HITS-CLIP clusters. Data is divided into those transcripts down-regulated or up-regulated in Nova DKO, as indicated. Sequence analysis of RT-PCR products showed the presence of cryptic exons harboring premature stop codons ([Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"}; [Supplementary file 2](#SD3-data){ref-type="supplementary-material"}). A diagram of the loci of each NMD exon present in Figure 5A is shown in [Figure 5---figure supplement 1](#fig5s2){ref-type="fig"}. For example, most transcripts down-regulated in Nova DKO brains show a larger, PTC containing exon in DKO; one exception is Actl6b, in which in the absence of NOVA there is a PTC, and in WT brain, an upper alternate isoform (exon) is present that corrects that frame-shift; (**B**) Effect of emetine on putative NOVA-regulated cryptic NMD exons. The steady-state level of six transcripts identified in [Figures 3B, 4C and 5A](#fig3 fig4 fig5){ref-type="fig"} were assessed by qRT-PCR in six DIV WT vs Nova DKO primary mouse neurons incubated for 10 hr in the presence or absence of emetine. The results were plotted with the Y-axis as a measure of the degree of putative NOVA-dependent NMD regulation (the fold change of transcript levels in DKO neurons in the presence or absence of emetine, divided by that of WT, in log~2~ scale). For example, for *Dlg3* the log~2~ value is about 1.0 indicating that emetine treatment increased the *Dlg3* NMD-isoform in DKO neurons relative to WT neurons by a factor of two, while emetine decreased the NMD isoform of *Scn9a* by ∼1.4-fold, leading to decrease or increase in the respective proteins in Nova DKO neurons ([Figures 2 and 3](#fig2 fig3){ref-type="fig"} or [Figure 4](#fig4){ref-type="fig"}, respectively). Three independent experiments were performed and error bars represent standard deviation (p\<0.05).**DOI:** [http://dx.doi.org/10.7554/eLife.00178.018](10.7554/eLife.00178.018)10.7554/eLife.00178.019Figure 5---figure supplement 1.Diagrams of each of the NMD exons shown in [Figure 5A](#fig5){ref-type="fig"}The position of the exon harboring a premature termination codon is labeled in red (PTC).**DOI:** [http://dx.doi.org/10.7554/eLife.00178.019](10.7554/eLife.00178.019)10.7554/eLife.00178.020Figure 5---figure supplement 2.NOVA regulates the expression of Stx2 (Syntaxin 2) mRNA and protein.(**A**) RT-PCR from WT and DKO brain showed NOVA-dependent alternative splicing of a previously unknown, higher molecular weight isoform of *Stx2*. A (−) RT negative control is shown. (**B**) Immunoblot analysis of STX2 protein in biologic triplicate samples of WT vs *Nova* DKO brain. γ-Tubulin was used as a normalization control. (**C**) Quantitation of relative protein intensity (WT/DKO) from (**B**), plotted as relative ratio of STX2 in WT/DKO; error bars represent standard deviation (p\<0.05). (**D**) Six DIV WT primary mouse culture were treated with vehicle (−) or emetine (+) for 10 hr and RT-PCR was performed for Stx2 as in (**A**). Quantitation revealed that the NMD exon (labeled) was increased twofold after emetine treatment. (**E**) DY547 direct-labeled siRNA targeting *Upf1* was transfected into WT mouse primary cells, and immunofluorescence microscopy used to detect STX2 (green) and siRNA to *Upf1* (red). The thin arrow (top right corner) indicates a cell which was not transfected with siRNA*,* and which shows a baseline signal of STX2 protein. The two thicker arrows indicate cells which had a good red signal (siRNA to *Upf1*) and stronger green signals (indicating increased STX2 protein). Scale bar: 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.020](10.7554/eLife.00178.020)

Dynamic control of NOVA-regulated NMD exons {#s2-7}
-------------------------------------------

To assess whether NOVA-dependent regulation of NMD exons is dynamic and physiologically relevant, we examined the effects of inducing seizures in vivo on the utilization of these alternative exons. Mice were treated with pilocarpine or sham to induce acute generalized seizures, using previously established protocols ([@bib76]). We assayed activity-dependent inclusion of NMD exons in *Scn9a*, *Cdk5rap2* and *Stx2*, which we had found to be included by NOVA in the resting brain. In each transcript, pilocarpine induced seizures correlated with clear increases in utilization of the NMD exon ([Figure 6A,B](#fig6){ref-type="fig"}), suggesting that the levels of these transcripts can be dynamically altered by electrical activity altering NOVA action.10.7554/eLife.00178.021Figure 6.Seizure-induced inhibition of NOVA-regulated NMD exons.(**A**) Mice were treated with pilocarpine (pilo) to induce seizures or were mock-treated (sham). 2 hr later brains were harvested and splicing of NMD exons assayed by RT-PCR. (**B**) Quantitation of experiments described in (**A**), from three biologic replicates. Error bars represent standard deviation (p\<0.05; Student\'s t-test). (**C**),(**D**) EEG of freely moving Nova2^+/−^ mutant displays frequent synchronous cortical interictal discharges (**C**) not detected in wild type mice (**D**). (**E**) Spontaneous generalized seizure discharge in adult Nova2^+/−^ mutant. A 20 s gap of continuous hypersynchronized EEG pattern separates the beginning and end of the seizure discharge. Bilateral left and right frontal, temporal, parietal (**C**, **D**) and occipital (**E**) leads are shown. Time calibration 1 s (**C**, **D**), 2 s (**E**).**DOI:** [http://dx.doi.org/10.7554/eLife.00178.021](10.7554/eLife.00178.021)10.7554/eLife.00178.022Figure 6---figure supplement 1.Comparison of different sets of transcripts regulated by NOVA.The number of transcripts in which NOVA regulates alternative splicing without changing steady-state mRNA levels are shown in blue, and in purple transcripts showing Nova-dependent changes in steady-state mRNA levels (e.g. through NMD or transcript stability). 340 transcripts in which cassette exons are regulated by NOVA were compiled from previous studies ([@bib79]; [@bib48]; [@bib90]), and compared with the 211 transcripts identified here by exon array. The datasets are largely mutually exclusive, with only 18 transcripts in common.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.022](10.7554/eLife.00178.022)

Pilocarpine can induce neuronal loss days after seizure ([@bib76]), although this is unlikely to be the case in these experiments, as RNA was analyzed 2 hr after seizure, and direct examination of neurons by immunofluorescence microscopy gave no indication of neuronal loss (see below, [Figure 7A](#fig7){ref-type="fig"}). Nonetheless, to assess whether this protocol, which induces neuronal stress, affects splicing in a global or specific manner, we examined global and Nova-dependent splicing changes at various times after pilocarpine induced seizures ([Table 3](#tbl3){ref-type="table"}).10.7554/eLife.00178.023Table 3.Splicing changes in brain after pilocarpine-induced seizures**DOI:** [http://dx.doi.org/10.7554/eLife.00178.023](10.7554/eLife.00178.023)\|ΔI t-test\| ≥ 5.6 (p\<0.005)4 hrTotalValidated\|ΔI t-test\| ≥ 0.472\|ΔI t-test\| ≥ 0.3215\|ΔI t-test\| ≥ 0.211722\|ΔI t-test\| ≥ 8.6 (p\<0.001)4 hrTotalValidated\|ΔI t-test\| ≥ 0.472\|ΔI t-test\| ≥ 0.3185\|ΔI t-test\| ≥ 0.29622\|ΔI\| ≥ 0.1524 hrTotalValidated\|ΔI\| ≥ 0.331\|ΔI\| ≥ 0.2236\|ΔI\| ≥ 0.15566[^2]

We first examined global changes in splicing using exon junction arrays at 4 hr and 24 hr after induction of pilocarpine seizure. Remarkably, there were very few splicing changes detected in the brain after pilocarpine seizure. Using stringent criteria (\|ΔI\| \> 0.2), only 23 exons showed differential splicing 24 hr after pilocarpine treatment, with more changes (96) evident 4 hr after pilocarpine treatment ([Supplementary file 1](#SD2-data){ref-type="supplementary-material"}); by contrast, using the same stringency, 1,239 exons showed differential splicing in brain relative to thymus tissue (\|ΔI\| \> 0.2; ([@bib81])). These results indicate that the regulation of alternative splicing is not globally perturbed within 24 hr of epileptic seizure in the mouse brain.

We validated exons that did show seizure-induced splicing changes, and examined their relationship to Nova-regulated exons. We measured the ratio of alternate exon inclusion:exclusion by RT-PCR, validating 35 targets at 4 hr and 24 hr time points ([Supplementary file 1](#SD2-data){ref-type="supplementary-material"}). GO analysis revealed that transcripts showing these changes showed a 7.5-fold enrichment of synaptic proteins, and a 5.2-fold enrichment for proteins with serine/threonine kinase activity, including SNAP25 and BDNF, proteins shown to play important roles during synaptic activity ([@bib89]; [@bib38]). We have previously found that NOVA regulates ∼800 alternate splicing events, about half of which are cassette exons ([@bib90]). We examined the 35 alternate exons that showed pilocarpine-dependent changes to see which were present on our list of Nova-dependent exons, and identified only eight as Nova-regulated ([Supplementary file 1](#SD2-data){ref-type="supplementary-material"}). These data indicate that only a small fraction of potential regulated alternate exons, including those regulated by Nova, are affected by seizure activity, and that pilocarpine does not appear to have a global impact on Nova splicing activity.

Cortical hyperexcitability and epilepsy in Nova2 heterozygous mice {#s2-8}
------------------------------------------------------------------

To further assess the relationship between Nova and epilepsy, we examined EEGs in Nova-null mice. However, Nova-null mice die by 2--3 weeks of birth, and we instead examined Nova-2 heterozygotes, which show partial defects (∼50% or less) changes in a number of NOVA regulated alternative exons ([@bib81]). Background cortical activity recorded in heterozygous mutants showed frequent bilateral synchronous cortical epileptiform discharges ([Figure 6C](#fig6){ref-type="fig"}) that were not seen in control +/+ mice ([Figure 6D](#fig6){ref-type="fig"}). A second abnormality observed was the spontaneous occurrence of generalized seizures ([Figure 6E](#fig6){ref-type="fig"}). Thus perturbing NOVA steady-state levels in vivo has relevant physiologic consequences, as haploinsufficiency is sufficient to give rise to spontaneous epilepsy in mice.

Activity-dependent changes in NOVA subcellular localization {#s2-9}
-----------------------------------------------------------

To further explore the relationship between electrical activity and NOVA action on splicing, we asked whether we could detect any acute effect of pilocarpine seizure on NOVA itself. We have previously demonstrated that NOVA shuttles between the nucleus and cytoplasm ([@bib67]), and hence explored the possibility that electrical activity might affect the cellular distribution of the protein. We examined NOVA subcellular localization by immunofluorescence microscopy after sham or pilocarpine induced seizures. We consistently observed marked shifts of NOVA from the neuronal nucleus to the cytoplasm within 2--4 hr of pilocarpine-induced seizures, and that persisted in some animals for 24 hr ([Figure 7A](#fig7){ref-type="fig"}). This finding was evident in cortical neurons, and even more so in the CA1 pyramidal neurons of the hippocampus, where quantitation revealed over a 6-fold shift in the ratio of nuclear to cytoplasmic signal intensity at 4 hr after seizure ([Figure 7B](#fig7){ref-type="fig"}). Consistent with the cortical nature of epilepsy, we did not see this shift in NOVA localization in Purkinje neurons of the cerebellum ([Figure 7A](#fig7){ref-type="fig"}). These data suggest that there may in part be cell biologic mechanisms whereby pilocarpine affects the ability of NOVA to regulate splicing of some targets, but additional experiments will be required to fully understand their nature and consequences.10.7554/eLife.00178.024Figure 7.NOVA subcellular localization after pilocarpine-induced status epilepticus.(**A**) NOVA and MAP2 protein localization were visualized by immunofluorescence (IF) in mouse brain sections from pilocarpine treated (pilo) or control animals (sham). Regions include CA1 and dentate gyrus (DG) from hippocampal area, cortex (Ctx) and cerebellar Purkinje neurons. Changes were clearly evident in CA1 neurons, were not evident in DG, and were variable in Ctx. No changes were expected nor observed in Purkinje neurons. (**B**) Quantification of IF signal intensity from nuclear area (Nuc) divided by signal intensity from cytoplasmic area (Cyt) in CA1 neurons. Nuc/Cyt ratios (sham divided by pilocarpine signal) were obtained from 22 cells in two sham animals and 23 cells in four pilocarpine animals at the 4 hr time point. Scale bar 20 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.024](10.7554/eLife.00178.024)

NOVA regulates some transcript levels by binding the 3′ UTR {#s2-10}
-----------------------------------------------------------

To further address the role NOVA plays in 3′ UTR regulation of mRNA steady-state levels, we searched for transcripts with a high percentage of 3′ UTR tags. We found that Synaptogyrin III (*Syngr3*), Glycine receptor B (*Glrb*) and the Gaba-B receptor1 (*Gabbr1*) had robust 3′ UTR CLIP tag clusters ([Figure 8A](#fig8){ref-type="fig"}). RNA levels quantitated by RT-PCR in WT or DKO brain demonstrated reduced levels of all three mRNAs in NOVA DKO ([Figure 8B](#fig8){ref-type="fig"}). Decrease of *Syngr3* mRNA in NOVA DKO was confirmed by Northern blot (∼20% reduction; [Figure 8C,D](#fig8){ref-type="fig"}) and at the protein level by Western blot (∼35% reduction [Figure 8E,F](#fig8){ref-type="fig"}).10.7554/eLife.00178.025Figure 8.NOVA regulates the expression of synaptogyrin III (Syngr3) mRNA and protein.(**A**) Location of cytoplasmic and nuclear CLIP for *Syngr3*. Red and purple colors represent Cytoplasmic CLIP tags and green and blue tags represent nuclear CLIP tags. All tags were located in 3′ UTR. (**B**) qRT-PCR data of *Syngr3*, *Glrb* (Glycine receptor b), and *Gabbr1* (GABA B receptor1) showed mild reduction (about 30%) in *Nova* DKO brain. Y-axis represents the relative mRNA levels (WT/DKO). p\<0.05. (**C**) Northern blot analysis of Syngr3 mRNA in WT (lane 1, 3, 5) vs DKO (lane 2, 4, 6). Gapdh probe was used as a normalizing control. (**D**) Quantitation of relative RNA intensity (WT/DKO) was plotted as a relative ratio of Syngr3 mRNA/Gapdh in *Nova* WT/DKO; error bars represent standard deviation (p\<0.05); Syngr3 was reduced by about ∼ 20% in DKO brain. (**E**) Immunoblot analysis of SYNGR3 in WT vs DKO. Protein extracts from WT (lane 1--4) vs DKO (lane 5--8) were loaded. γ-TUBULIN is used as a normalizing control. (**F**) Quantitation of relative protein intensity (WT/DKO). The results were plotted as relative ratio of SYNGR3 in WT/DKO; error bars represent standard deviation (p\<0.05); SYNGR3 protein was reduced ∼35% in DKO brain.**DOI:** [http://dx.doi.org/10.7554/eLife.00178.025](10.7554/eLife.00178.025)

To address whether direct NOVA binding to the *Syngr3* or other 3′ UTR (YCAY) elements could stabilize mRNA, we generated reporter constructs in which EGFP was generated from a transcript harboring WT or YAAY-mutated NOVA 3′ UTR binding sites defined by CLIP ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). After transfecting each construct into N2a cell lines, cells were treated with actinomycin D for 5 hr to block new RNA synthesis, and qRT-PCR was performed to measure mRNA levels of each construct. These data showed that transcripts containing 3′ UTR YCAY elements were stabilized relative to those harboring YAAY elements (by a factor of 25--65%) compared to YAAY elements ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Taken together ([Figure 8](#fig8){ref-type="fig"} and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), these data suggest NOVA protein is able to regulate mRNA levels through direct binding to 3′ UTR YCAY elements.

NOVA-regulated RNAs are enriched in synaptic function related genes {#s2-11}
-------------------------------------------------------------------

To investigate whether transcripts whose steady-state levels are NOVA-regulated are more enriched in certain functional classes of genes than others, we analyzed the functional annotations associated with 229 genes from exon array data ([Figure 1A](#fig1){ref-type="fig"}) using GO analysis ([Table 4](#tbl4){ref-type="table"}). We found that these transcripts encode proteins that regulate synaptic biology or transport. We compared this set of transcripts with those previously found to be regulated by NOVA at the level of alternative splicing but without changes in steady-state mRNA levels. Interestingly, while both sets of transcripts encode proteins related to synaptic function, only 18 genes overlap between the two sets ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). This implies that the set of functions NOVA regulates at steady-state level differ significantly from those functions NOVA regulated strictly at the level of alternative splicing.10.7554/eLife.00178.026Table 4.GO analysis**DOI:** [http://dx.doi.org/10.7554/eLife.00178.026](10.7554/eLife.00178.026)TermCount%p-ValueFoldBenjaminiBiological processTransport5727.67%1.40 × 10^−08^2.107796017.27 × 10^−05^Establishment of localization5727.67%3.74 × 10^−08^2.05127419.71 × 10^−05^Localization6029.13%1.46 × 10^−07^1.919082552.53 × 10^−04^Ion transport2512.14%1.50 × 10^−06^3.081180050.001943Synaptic transmission125.83%1.16 × 10^−05^5.495306530.011935Chloride transport73.40%4.92 × 10^−05^10.56844760.041641Transmission of nerve impulse125.83%6.38 × 10^−05^4.564998730.04624Exocytosis83.88%6.71 × 10^−05^7.887820930.042589Cation transport178.25%1.41 × 10^−04^3.041923540.07808Metal ion transport157.28%1.72 × 10^−04^3.309102960.085535Cell--cell signaling136.31%4.67 × 10^−04^3.376708290.197738Cellular componentSynapse199.22%1.69 × 10^−10^7.127249051.33 × 10^−07^Postsynaptic membrane125.83%3.96 × 10^−08^9.732800981.55 × 10^−05^Synapse part125.83%1.25 × 10^−07^8.712426693.27 × 10^−05^Cytoplasmic part6632.04%1.11 × 10^−06^1.758471442.17 × 10^−04^Cell junction188.74%2.18 × 10^−06^4.051278413.42 × 10^−04^Cytoplasm9144.17%1.52 × 10^−05^1.444390910.00198Plasma membrane4421.36%5.11 × 10^−05^1.856255860.005706Molecular functionIon transmembrane transporter activity3014.56%1.74 × 10^−10^4.092340244.70 × 10^−07^Transporter activity4220.39%4.86 × 10^−10^2.914748466.58 × 10^−07^Substrate-specific transmembrane transporter3115.05%1.15 × 10^−09^3.657581911.04 × 10^−06^Transmembrane transporter activity3316.02%2.22 × 10^−09^3.364131521.50 × 10^−06^Substrate-specific transporter activity3316.02%1.85 × 10^−08^3.080489069.99 × 10^−06^Gated channel activity178.25%3.63 × 10^−08^5.822507111.64 × 10^−05^Ligand-gated channel activity115.34%5.03 × 10^−08^11.14219451.70 × 10^−05^Ligand-gated ion channel activity115.34%5.03 × 10^−08^11.14219451.70 × 10^−05^Anion transmembrane transporter activity125.83%6.01 × 10^−08^9.365421271.81 × 10^−05^Ion channel activity188.74%2.53 × 10^−07^4.73445336.84 × 10^−05^Substrate specific channel activity188.74%3.85 × 10^−07^4.594831359.47 × 10^−05^GO term analysis (top increase in DKO 14 genes)Biological processVesicle-mediated transport321.43%0.0226511.020603435.4494Molecular functionBinding1178.57%0.0311261.414615191Transporter activity428.57%0.0450364.340577791Protein binding964.29%0.0051922.312627480.999999[^3]

Discussion {#s3}
==========

Regulation of steady-state mRNA levels plays a key role in cellular and neuronal plasticity, allowing tunable and dynamic regulation of protein output. Such regulation is generally thought to be mediated by RNA--protein interactions in the 3′ UTR, which may involve interactions with a number of RNA binding proteins. For example, the balance of binding to AU-rich elements by AUF1, BRF1, KSRP, TTP or HuR ([@bib56]), binding to UGUR elements by Pumillio ([@bib8]; [@bib66]), or interactions between miRNAs and the Ago--RISC complex ([@bib42]) all feed into pathways of deadenylation and mRNA decay. Our finding that transcripts showing NOVA-dependent steady-state regulation did not have NOVA binding sites in the 3′ UTR was therefore unexpected, and might have suggested that these were indirect targets of NOVA action. However, HITS-CLIP provides a powerful means of providing unambiguous and unbiased sites of RNA--protein interaction. Directed analysis of unbiased HITS-CLIP targets can reveal cryptic biology, as in the analysis of developmental HITS-CLIP maps to study NOVA interactions with transcripts of the Reelin pathway and thereby identify a previously unknown NOVA-dependent alternative exon necessary for proper neuronal migration ([@bib86]). Here, we have used the predictive power of HITS-CLIP to identify seemingly irrelevant intronic NOVA binding sites on transcripts showing unexplained NOVA-dependent steady-state changes to predict the presence of cryptic alternative NMD exons.

NOVA-regulated splicing controls mRNA levels by NMD {#s3-1}
---------------------------------------------------

NMD is an RNA surveillance mechanism that degrades mRNAs harboring premature termination codons (PTC), and is generally thought of as a means to protect cells from inadvertently producing truncated proteins that could be harmful to the cell. Such transcripts harbor downstream exon junction complex (EJC) proteins that, due to upstream PTCs, fail to be removed during an initial round of translation, leading to recruitment of NMD components ([@bib72]). Recent studies have extended this view, indicating that NMD can function beyond a quality control mechanism, to serve as a mechanism for regulating gene expression disability ([@bib30]). NMD efficiency varies in different tissues, loss-of-function mutations in Upf genes in mice alter expression of a subset of transcripts, and loss-of-function mutations in Upf3b in humans are associated with intellectual disability ([@bib75]).

Regulated alternative splicing of NMD exons has also been shown to act as a mechanism to regulate transcript levels, as in the case of autoregulation of splicing factors such as SC35, Ptbp1 and 9G8 ([@bib44]), as well as core components of the spliceosome ([@bib70]). In addition, alternative splicing-coupled NMD has been shown to regulate expression levels of Arc ([@bib22]), PSD95 ([@bib91]), and spermine acetyltransferase ([@bib33]), a process referred to as regulated unproductive splicing and translation (RUST) ([@bib44]). In yeast, a direct role for NMD was statistically inferred in the regulation of hundreds of transcripts involved in chromosomal and telomere maintenance and silencing ([@bib26]). Cancer cells have been shown to utilize NMD, for example via actions on mutant cadherin transcripts (*Chd1*) that are associated with poor clinical outcome in hereditary diffuse gastric cancer. A full understanding of such pathways and means to manipulate them has been challenging because the factors regulating NMD-associated splicing are not generally known. Some well-studied exceptions have provided significant biologic insights, such as the autoregulation of the splicing factor PTBP1 ([@bib83]) and its action on the paralogous transcript PTBP2, which mediates skipping of Ptbp2 exon 10, leading to NMD and suppression of neuronal differentiation ([@bib2]; [@bib50]). Indeed, Makeyev and co-workers have identified PTBP1-dependent retained introns that suppress expression of neuronal transcripts in non-neuronal cells, allowing their expression as PTBP1 is downregulated during neuronal differentiation ([@bib87]). We recently found that PTBP2 is expressed in neuronal progenitors, while NOVA is induced in post-mitotic neurons ([@bib86]; [@bib49]); regulation of cryptic exon splicing may affect transcript levels in neurons and/or prevent spurious expression of transcripts in non-neural cells. Another point of interest will be to assess whether there is cell-type specific regulation of PTC exons in specific neuronal types within the adult brain in a manner analogous to PTBP1 regulation of expression within different tissues of the body.

Here we show the frequent use of trans-acting control by a single neuronal splicing factor, NOVA, to regulate an array of target transcripts. This mechanism is biologically rich, as it includes both the up- and down-regulation of target RNAs through alternative splicing coupled to NMD in neuron. The regulatory roles of these actions are underscored by our observation that the cryptic NMD exons NOVA acts upon are evolutionarily conserved (Zhang and Darnell, manuscript in preparation), suggesting a regulatory rather than quality-control NOVA function. Taken together, our data suggest a model in which NOVA regulation maintains a balance of transcript levels through NOVA-dependent alternative splicing coupled NMD and, to a lesser degree, through direct interaction with 3′ UTR binding elements ([Figure 9](#fig9){ref-type="fig"}).10.7554/eLife.00178.027Figure 9.Model linking electrical activity with Nova-dependent splicing of cryptic NMD exons to maintain the balance of synaptic proteins.In WT brain, NOVA represses some cryptic NMD isoforms (small red diamonds on left) while promoting others (large red pentagons on right), thereby maintaining the balance of protein levels. To a lesser degree, NOVA also stabilizes transcripts through 3′ UTR interactions ([Figure 8](#fig8){ref-type="fig"}). In DKO brain, the absence of NOVA disturbs this balance of protein in expression, contributing to aberrations in synaptic transmission. For example, Nova-regulation of cryptic NMD exons alters levels of the NMDA-receptor associated *Dlg3* ([Figures 2 and 3](#fig2 fig3){ref-type="fig"}) and sodium channel *Scn9a* ([Figure 4](#fig4){ref-type="fig"}) proteins, which are implicated in familial epileptic disorders and are dynamically regulated after seizures in mice ([Figure 6](#fig6){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.00178.027](10.7554/eLife.00178.027)

We found that NOVA mediated NMD-coupled splicing can be dynamically regulated in the brain. This suggests in turn that NOVA activity may be regulated by such dynamic events, leading to changes in RNA regulation and ultimately changes in neuronal proteins. The mechanisms that regulate NOVA are largely unknown, but interestingly, NOVA may be phosphorylated by GSK3 ([@bib17]), which itself is known to be inactivated in response to various extracellular stimuli in the brain, stimulating pathways such as the PI3K/Akt pathway ([@bib32]), which are activated by electrical activity ([@bib68]). Thus it is possible that neuronal cell dynamics lead to fine tuning of RNA processing and expression through RNA binding proteins that act as sensors of electrical activity.

NOVA-regulated NMD-coupled splicing and epilepsy {#s3-2}
------------------------------------------------

There is growing interest in the relationship between alternative splicing and neuronal excitability in the brain, as underscored by the recent finding that loss of the splicing factor Rbfox1 results in increased susceptibility to seizures and concomitant splicing changes in transcripts encoding synaptic proteins ([@bib21]). Interestingly, NOVA interacts functionally with Rbfox1 ([@bib90]), and many of the proteins showing large Nova-dependent changes are also involved in synaptic regulation with links to epilepsy were also found to have NOVA-dependent NMD exons regulated after induction of seizures in mice. For example, NOVA regulation of NMD splicing controls the levels of DLG3, one of a family of postsynaptic density proteins, including PSD95, that transduce signals from the NMDA receptor. Increases in both PSD95 ([@bib88]) and DLG3 ([@bib65]) in cortex or post-synaptic fractions, respectively, have been described in brains of patients with focal cortical dysplasia and epilepsy. NOVA regulation of NMD splicing also controls the levels of SCN9a, a sodium channel initially thought to act primarily in dorsal root ganglia ([@bib55]) (neurons that do not express NOVA proteins ([@bib5])), but more recently found to be mutated in human epilepsy (causing familial febrile seizures; ([@bib73])). Other NOVA-NMD related targets in which gene mutations have been implicated in human epilepsy include the anion transporters SLC4a10 and SLC4a3 ([Table 1](#tbl1){ref-type="table"}; ([@bib27]; [@bib71])).

The observation that either induction or loss of the same protein activity may be associated with epilepsy, suggest that the proper stoichiometry of synaptic proteins (or protein activity), rather than their absolute amount, may be a key determinant in electrical balance ([Figure 8](#fig8){ref-type="fig"}). This correlates with our observation that NOVA haploinsufficiency is sufficient to induce spontaneous epilepsy ([Figure 6](#fig6){ref-type="fig"}), an observation also made with the neuronal RNABP Elavl3 and Elavl4 ([@bib34]). Moreover, NOVA control of NMD exons can act to either up or down-regulate protein levels generated from target transcripts, and, more specifically, to act after seizure to restore balance to synaptic proteins that would inhibit further seizure (e.g. increasing SCN9a, which would presumably be anti-epileptic). Hence the normal regulation of NOVA itself may provide an RNA-based means of regulating homeostatic plasticity in the face of electrical stress.

New links between nuclear and cytoplasm RNA regulation {#s3-3}
------------------------------------------------------

We have previously found that NOVA regulates neuronal alternative splicing, and that steady-state levels of these regulated transcripts are not significantly altered in *Nova* KO mice ([@bib81]; [@bib48]). The observation here of a significant set of transcripts undergoing NOVA-dependent regulation of steady-state levels on the surface therefore initially suggested that this was an independent set of NOVA actions. However, our finding that these were disproportionately NOVA-mediated actions to maintain neuronal transcript levels (215 vs 14) is consistent with an overall action linking alternative splicing suppression of NMD exons to steady-state transcript levels.

Interestingly, our data also suggested a more general link between splicing and mRNA stability. Among transcripts with NOVA 3′ UTR binding we observed a significant number also had intronic NOVA binding, suggesting a possible hierarchy of events in which nuclear binding precedes (and potentially determines) 3′ UTR binding. Such connections were originally suggested from studies in *Drosophila*, in demonstration of the coupling of the splicing and localization of Oskar mRNA ([@bib28]), and the observation that the predominantly nuclear Hrb27c protein (whose mammalian homologue is the DAZAP1 splicing factor; ([@bib23])) also binds to and is required for localization of *Grk* mRNA ([@bib24]). In mammalian cells, ZBP1 binds to actin mRNA in the nucleus and subsequently is required for its localization ([@bib25]; [@bib61]), and NOVA binds to transcripts (e.g. GlyRα2) in introns to regulate alternative splicing and is also associated with 3′ UTR and localization of the same mRNA in the neuronal dendrite ([@bib67]).

One potential explanation for such observations, as well as for the link between nuclear and cytoplasmic NOVA tags seen here, would be reassortment of transcripts in cis on individual transcripts, providing a means of linking nuclear functions such as alternative splicing with cytoplasmic function such as RNA localization or RNA stability. For example, intronic NOVA binding to high affinity intronic clusters would allow a high local concentration of the protein upon individual transcripts, potentially allowing rearrangement in cis and binding of additional secondary RNA elements, including those within the 3′ UTR. However, it should be noted that HITS-CLIP provides data that is a population average of many individual RNA--protein interactions, so that such potential cis-actions on a single transcript can only be inferred. Nonetheless, it is noteworthy that such local concentration and one-dimensional rearrangements *in cis* are believed to play an important role in scanning and initiation of transcription ([@bib1]; [@bib82]), and hence may plausibly act on pre-mRNAs to distribute RNABPs *in cis* to coordinate different aspects of post-transcriptional regulation. In this context, it is especially notable that NOVA localization changes after seizure, suggesting that the association of NOVA with newly transcribed and spliced transcripts may be coupled in an activity-sensitive manner with their localization and/or translational control.

Summary {#s4}
=======

We identified transcripts that show NOVA-dependent changes in steady-state levels in KO mice and used HITS-CLIP to drive the unexpected observation that what appeared to be functionless NOVA intronic binding sites in unregulated regions of these pre-mRNAs do function to regulate expression of cryptic NMD exons. These were enriched in transcripts encoding synaptic proteins, and their regulation mediated large changes in protein levels (up or down), including proteins implicated in familial epilepsy. The link between NOVA and regulation of excitation/inhibition balance was supported by finding that NOVA haploinsufficient mice had spontaneous epilepsy, and that pilocarpine-induced seizures regulated inclusion of a relatively small number of exons, a subset of which are regulated by Nova. Moreover, Nova redistributes from the nucleus to cytoplasm following pilocarpine seizure, and providing a possible mechanism underlying seizure-associated splicing changes involving Nova-regulated exons. Collectively, our data support a model in which changes in electrical activity affect the distribution of Nova, altering the splicing of cryptic exons that elicit NMD; these changes may provide a homeostatic means of regulating levels of transcripts and proteins associated with epilepsy.

Materials and methods {#s5}
=====================

Plasmid constructs {#s5-1}
------------------

YCAY elements were amplified by PCR and added into the pd1EGFP vector (Clontech, CA). Mutations to YCAY elements were made by using QuickChange site-directed mutagenesis kit (Stratagene, CA). Primers are listed in [Supplementary file 2](#SD3-data){ref-type="supplementary-material"}. RT-PCR products were cloned by using pGEM-T-easy Vector system (Promega, WI) and then sequenced (Genewiz, NJ).

Nuclear/cytoplasmic fractionation {#s5-2}
---------------------------------

Two fractionation methods were used. In the first, P13 wild type mouse cortex was, dissociated and then UV irradiated for CLIP (3 × 400 mJ/cm^2^) in a Stratalinker (Stratagene), and fractionation was performed as recommended with a commercial kit (BioVision, CA). In the second method, P13 mice were used. The brain cortex was dissected of white matter, chopped and irradiated (3 × 400 mJ/cm^2^) in HBSS (Invitrogen, NY) containing 0.01 M HEPES (pH 7.3) in a Stratalinker. Tissue was Dounce homogenized in cold gradient buffer (20 mM HEPES \[pH 7.4\], 150 mM NaCl, 5 mM MgCl~2~, 0.5 mM DTT, protease inhibitor \[Roche, NJ\] and RNasin Plus RNase inhibitor \[Promega, WI\]). The homogenized tissue was then treated with 0.5% NP-40 on ice and centrifuged 2× at 2000×*g* for 10 min, and the resultant supernatant was collected as the cytoplasmic fraction.

Western blot analysis {#s5-3}
---------------------

Protein extracts (nuclear/cytoplasmic fractions and WT vs DKO brain extracts from P13 and E18.5 whole brains, respectively) were resolved by 10% SDS-PAGE and transferred to PVDF membranes (Millipore, MA). Membrane was blocked and incubated with primary antibodies including goat anti-NOVA2; mouse anti-HSP90, mouse anti-HNRNP-C1, mouse anti-DLG3 (SAP102), mouse anti-SCN9a, rabbit anti-SYNGR3, rabbit anti-STX2 and mouse anti-γ-tubulin. Three different mouse brains were used as biological replicates as indicated throughout.

RNA analysis {#s5-4}
------------

### Exon arrays in E18.5 mouse brain {#s5-4-1}

For estimating the level of brain transcripts, total RNAs from four E18.5 mouse brains were extracted using Trizol (Invitrogen, NY) and RNAeasy kit (Qiagen, CA) and mRNA was amplified and labeled by the method provided by Affymetrix. Mouse MoEx 1.0ST Arrays were used for measuring signal intensity of each exon in the samples. To process the signals from the array, quantile normalization (WT vs DKO) and PM-GCBG (signal adjustment based on the background with similar GC content) were applied.

Steady state RNA levels were assessed using Affymetrix Mouse MoEx 1.0ST Exon arrays (Affymetrix, CA), and analyzed with Affymetrix Power Tools using IterPLIER. IterPLIER was used for selecting appropriate 'core exon' probes to estimate gene-level intensities. Finally, median log~2~ values from four biological replicates are used to estimate level of transcripts in the E18.5 brain in WT vs DKO.

Interrogation and analysis of Affymetrix Exon junction arrays was undertaken as previously described, using the ASPIRE and ASPIRE2 programs ([@bib81]; [@bib34]).

### RT-PCR and qRT-PCR {#s5-4-2}

cDNA was generated by using random hexamers and Superscript III (Invitrogen, NY). Once the number of PCR cycle was tested for the linear range, ^32^P-dCTP was added into the PCR reactions for the last two cycles and then run onto denaturing gels (6% polyarylamide/7 M urea). It was exposed to X-ray film (Kodak, NY). Quantitative RT-PCR (qRT-PCR) was performed by using a MyiQ single-color real time PCR detection system (Biorad, CA), using mouse tubulin as an internal control, and relative mRNA level (WT vs DKO) was calculated by ΔΔCt values. All qRT-PCR was performed in RNA from at least three biological replicates. qRT-PCR and other PCR primers are listed in [Supplementary file 2](#SD3-data){ref-type="supplementary-material"}.

### Northern blot analysis {#s5-4-3}

Total RNA (10 μg) was electrophoresed and transferred into the Nylon membrane (Ambion, CA). The cDNA fragments complementary to *Dlg3* (digested by XmaI and BspE1), *Syngr3* (primers as below) and *Gapdh* (Ambion, CA) were labeled with ^32^P-dCTP using prime II random label kit (Stratagene, CA). The membrane was hybridized with ^32^P-labeled probes at 45°C overnight. After several washes, the membrane was exposed to X-ray film (Kodak, NY).

HITS-CLIP and bioinformatics {#s5-5}
----------------------------

NOVA HITS-CLIP was performed on subcellular fractions using previously described protocols ([@bib79], [@bib78]; [@bib36]; [@bib48]). High-throughput sequencing was performed on an Illumina GAIIx. CLIP tags were analyzed as previously described ([@bib48]), with modifications as described below.

### Genomic mapping of illumina reads {#s5-5-1}

Sequencing reads were first filtered by the default Illumina pipeline. Filtered reads were then mapped by Eland using different sizes from 25 to 32 nt, with at most two mismatches ([@bib90]). A read is kept for analysis only if it was mapped to an unambiguous locus with at least one particular size. If unambiguous mapping was possible with different sizes, the one with largest size, yet without increasing number of mismatches was kept. Overall, 57% of reads are unambiguously mappable ([Table 2](#tbl2){ref-type="table"}).

For each individual CLIP experiments, we further collapsed reads with the same start genomic coordinates to remove potential RT-PCR artifacts. As a result, 1.3 million nuclear CLIP tags and 0.2 million cytoplasmic CLIP tags were unique and used for further analysis ([Table 2](#tbl2){ref-type="table"}).

### Definition of CLIP clusters {#s5-5-2}

To generate a reliable definition of CLIP clusters, we used a cohort of ∼20 independent NOVA CLIP experiments. CLIP clusters were identified by a Hidden Markov Model (HMM), which will be described in detail elsewhere. For each of the clusters, the number of CLIP tags for each nuclear and cytoplasmic CLIP experiment was counted. Only clusters with ≥2 tags in the nuclear/cytoplasmic tags were kept for this study (81,162 clusters). To measure the robustness of each cluster, biological complexity (BC) was defined as the number of samples with at least 1 tag in the cluster. BC was calculated for nuclear and cytoplasmic CLIP experiments, respectively. For each cluster, we also count the number of tags overlapping with each position and define peak height by the maximum number of overlapping tags.

GO analysis was performed by using DAVID (<http://david.abcc.ncifcrf.gov/>).

Antibodies {#s5-6}
----------

Human sera from POMA patients was used to detect NOVA proteins in mixed cultured neurons. HSP-90 antibody (BD biosciences, CA), γ-tubulin (GTU88) antibody (Sigma, MO), hnRNP-C1/C2 antibody (Abcam, MA), NOVA2 antibody (Santa Cruz, CA) DLG3 (SAP102) and SCN9a antibodies (neuro-Mab, CA), STX2 antibody (Synaptic Systems, Germany), Neurofilament M antibody (Millipore, MA), UPF1 antibody (Dr Lykke-Andersen) and SYNGR3 antibody (Dr Janz) were used. All secondary antibodies mouse, rabbit, goat and human HRP- and Cy2/Cy3/Cy5-conjugated antibodies are from Jackson Immuno Research Laboratories, PA.

Primary mouse neuronal culture and emetine treatment {#s5-7}
----------------------------------------------------

Primary mouse neuronal cultures were generated from E18.5 cortical neurons prepared as previously described ([@bib19]). In brief, forebrain from embryonic 18.5 days mouse brain (WT and DKO) was dissected, trypsinized, and plated on poly-l-lysine coated coverslips and dishes (BD biosciences, CA) in neurobasal medium (Invitrogen, NY) for immunofluorescence and cultured for 10 days at 37°C in 5% CO~2~ and transfection with nucleofection was performed before plating. Emetine (100 μg/ml; Sigma, MO) was added to cells grown for 6 days in vitro (DIV) WT/DKO cultures for 10 hr.

Primary mouse neuronal cultures and N2a cells were transfected with siRNA ON-TARGETplus SMARTpool (Dharmacon, PA) and DY547 conjugated siRNAs by nucleofection (Lonza, NJ) as described by manufacturers. 48 hr after transfection with a SMARTpool of four siRNAs to *Upf1* or an equimolar amount of non-targeting control siRNAs (Dharmacon, PA), the cells were fixed in paraformaldehyde (4% in PBS) at room temperature for 15 min for immunofluorescence and RNA was extracted for RT-PCR.

Immunofluorescence {#s5-8}
------------------

Immunofluorescence was performed as described ([@bib67]) with the following modifications. After fixation, coverslips were incubated for 1 hr at room temperature in Tri Buffered Saline (TBS) with BSA (2%), FBS (2%) and Triton X-100 (0.1%). Primary antibody incubations were for another 1 hr at the same condition with BSA (1%) and Triton X-100 (0.1%). All secondary antibodies were affinity-purified donkey antibodies to mouse, rabbit or human IgG conjugated to a Cy2/Cy3/Cy5 (Jackson Immuno Research Laboratories, PA). Coverslips were mounted with prolong gold antifade reagent (Invitrogen, NY) after DAPI (4,6-diamidino-2-phenylindole dihydrochloride) staining the cells.

Pilocarpine treatment {#s5-9}
---------------------

Seizures were induced as follows: 8-week old mice were given subcutaneous injection of methyl scopolamine nitrate (1 mg/kg). After 30 min, mice were given subcutaneous injection of pilocarpine (320--340 mg/kg). After 2 hr, RNA was extracted from brain (pilo vs sham) and RT-PCR was performed.

Chronic electroencephalographic (EEG) recordings {#s5-10}
------------------------------------------------

Adult *Nova2* (*-/+*) and wild-type (+/+) mice (aged 6--9 months) were implanted for chronic EEG recordings. Mice were anesthetized with Avertin (1.25% tribromoethanol/amyl alcohol solution, i.p.) using a dose of 0.02 ml/g. Teflon-coated silver wire electrodes (0.005 inch diameter) soldered to a microminiature connector were implanted bilaterally into the subdural space over frontal, temporal, parietal, and occipital cortices. Digital EEG activity was monitored daily for up to 2 weeks during prolonged overnight and random 2 hr sample recordings (Stellate Systems, CA, Harmonie software version 6.0b). A digital video camera was used to simultaneously monitor behavior during the EEG recording periods. All recordings were carried out at least 24 hr after surgery on mice freely moving in the test cage.
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###### List of validated targets that were alternatively spliced after pilocarpine induced status epilepticus.

Targets were grouped according to their biological process and molecular function. Calculated delta I (ΔI) was listed for both the hippocampus (Hp) and cortex (Ctx) at 4 hr and 24 hr time points. ΔI from exon junction arrays are listed; other exons were empirically examined. Total fold change (TFC) of transcript level was calculated as the signal from status epilepticus divided by the signal of sham in the hippocampus. Alternative splice (AS) type is also listed, with abbreviations as follows: CASS: cassette exon; ALT5: alternative 5′ splice sites; ALT3: alternative 3′ splice sites; MUTX: mutually exclusive exons; IRET: retained intron; APA3: alternative polyA usage coupled with 3′ splice site selection; ALTP: alternative promoter; TACA: tandem cassette exons.

**DOI:** [http://dx.doi.org/10.7554/eLife.00178.028](10.7554/eLife.00178.028)
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###### 

PCR primers used in this work. All PCR primers are shown, oriented 5′ to 3′.

**DOI:** [http://dx.doi.org/10.7554/eLife.00178.029](10.7554/eLife.00178.029)
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://www.elifesciences.org/the-journal/review-process)). Similarly, the author response typicalsly shows only responses to the major concerns raised by the reviewers.

Thank you for choosing to send your work entitled "NOVA-dependent regulation of occult NMD exons controls synaptic protein levels after seizure" for consideration at *eLife*. Your article has been evaluated by a Senior Editor and 3 reviewers, one of whom is a member of *eLife\'s* Board of Reviewing Editors. The following individuals responsible for the peer review of your submission want to reveal their identity: Ben Blencowe and Doug Black.

The Reviewing Editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing Editor has assembled the following comments based on the reviewers\' reports.

In this manuscript, Eom and colleagues investigate the molecular basis by which the neural-specific splicing regulator Nova controls the levels of transcripts and corresponding proteins with important functions in the synapse. Using microarray profiling they detect ∼200 genes with increased transcript levels in the brains of wild-type mice compared to brains of *Nova1*/*Nova2* double knockout (DKO) mice. A much smaller number of genes show the opposite behavior. Using HITS-CLIP data, the authors examine the nuclear-cytoplasmic distribution of Nova binding sites in transcripts with differences in steady-state levels. While Nova binding to 3′UTR sequences appears to control the levels of some transcripts, a more widespread mechanism involves Nova binding within intronic sequences adjacent to previously unannotated exons, referred to as "occult exons" by the authors. Nova-dependent suppression or activation of the PTC-introducing exons promotes increased or decreased transcript/protein levels, respectively. The authors further use pilocarpine-induced seizures to investigate how changes in electrical activity might impact Nova-dependent regulation of transcript levels.

The results described are interesting and will appeal to researchers in the fields of gene regulation and neurobiology. Although regulation of transcript levels via alternative splicing coupled to NMD has already been described in several biological contexts, the identification of a coherent network of splicing events subject to this mode of regulation, with potentially important roles in the synapse, is a significant advance. Moreover, the use of HITS-CLIP to identify novel exons that function in regulating transcript levels is a clever application of an already powerful genome-wide approach. The reviewers have several concerns that they would like to see addressed in a revised manuscript.

1\. The authors conclude from their experiments involving pilocarpine-induced seizures that the "clear increases in utilization of the NMD exon suggest that the levels of these transcripts can be dynamically tuned by electrical activity". However, pilocarpine-induced seizures are known to cause oxidative damage and neuronal loss (e.g., Turski et al. 1986, which the authors cite). The authors should attempt to address whether this treatment directly impacts Nova-dependent splicing activity. At the very least, they should mention the caveats of this experiment, soften their conclusions, and modify the manuscript title.

2\. A possible alternative model for the physiological relevance of the authors\' findings is that the Nova-dependent suppression of cryptic exons serves as a mechanism to ensure that specific neuronal transcripts are not spuriously expressed in non-neuronal cells. The authors could readily test this by performing RT-PCR assays on the Nova-regulated transcripts, +/- *Upf1* knockdown, in non-neural cells. In this context, it is worth noting related work of Makeyev and co-workers (*G&D* 26, 1209; 2012), who have identified a class of Ptbp1-dependent retained introns that suppress expression of neural transcripts in non-neural cells.

3\. The authors utilize a liberal cutoff in their identification of differentially expressed genes from their microarray analysis. A magnitude log~2~ change of 0.3 corresponds to slightly less than a 1.25 fold ratio change, and given the noise inherent in microarray measurements, it is unlikely that estimated changes in this range will validate at the same rate as those changes estimated to be \>1.5 fold. Accordingly, the authors are requested to use qRT-PCR assays over the range of 229 genes predicted to show expression differences to assess false-positive rates. In this context, the descriptor "widespread" may be overstated.

10.7554/eLife.00178.031

Author response

*1. The authors conclude from their experiments involving pilocarpine-induced seizures that the "clear increases in utilization of the NMD exon suggest that the levels of these transcripts can be dynamically tuned by electrical activity". However, pilocarpine-induced seizures are known to cause oxidative damage and neuronal loss (e.g., Turski et al. 1986, which the authors cite). The authors should attempt to address whether this treatment directly impacts Nova-dependent splicing activity. At the very least, they should mention the caveats of this experiment, soften their conclusions, and modify the manuscript title*.

We agree with the reviewers that being more circumspect here is prudent and we have revised the text to include caveats along the lines suggested. We specifically address the issue of whether neuronal loss could account for our data below and in the revised text ("Pilocarpine can induce neuronal loss days after seizure (Turski et al., 1986)...").

We have taken the reviewers\' advice and examined whether this treatment impacts Nova-dependent splicing activity more generally. We have considered carefully our response particularly in light of the editorial policy at *eLife*, which seems to be governed by good sense in providing consensus and focus to reviewer comments and efforts to avoid onerous burdens proposing new lines of research in response to the reviews. We applaud this approach, recognizing that unreasonable demands for additional manuscripts\' worth of data may be made by other top-tier journals, and that *eLife* wishes to avoid such demands. At the same time, we interpret *eLife* policy as allowing a reasonable degree of discretion in the detail with which authors choose to respond to the reviewers\' questions. In this case, we have responded to the reviewers\' comment that we "should attempt to address" Nova\'s effects on splicing, which we interpret as a suggestion (and not a demand) by doing the full experiment, and we now report the results in this revision in tremendous detail. We include a large amount of very high quality experimental data that we were planning to use as the basis for a separate manuscript. Our intention here is to strengthen the paper significantly, and also to pay genuine respect the reviewers\' concerns and to the ethos of the new *eLife* journal itself, by responding to the option to do additional work with the maximum, rather than minimum, response.

In the revised manuscript, we present new experiments analyzing splicing data in mouse brain in various regions (hippocampus and cortex), at different timepoints (4 and 24 hours) and using several platforms (exon junction arrays and RNA-Seq). We go on to experimentally validate this data, and to overlay this analysis with an examination of Nova-dependent splicing as requested. We supplement this validation of RNA levels by examining Nova-dependent cell biology with a completely new finding that may be impacting Nova\'s effects on the splicing of some transcripts. Finally, we document the physiologic relevance of the Nova-dependent/activity-dependent splicing and cell distribution changes in aggregate by showing that Nova2 KO and indeed, heterozygous mice, have spontaneous seizures.

These new data are presented in the sections entitled "Dynamic control of NOVA-regulated NMD exons", "Cortical hyperexcitability and epilepsy in Nova2 heterozygous mice", and "Activity-dependent changes in NOVA subcellular localization". In sum, the new experiments address in molecular and cell biologic detail the effects of pilocarpine-induced seizures on Nova biology, and further tie Nova biology to naturally occurring seizures in the haploinsufficient state.

More precisely, in response to the reviewers\' question, these new data allow us to conclude the following:

"We examined the 35 alternate exons that showed pilocarpine-dependent changes to see which were present on our list of Nova-dependent exons, and identified only 8 as Nova-regulated (Table 3). These data indicate that only a small fraction of potential regulated alternate exons, including those regulated by Nova, are affected by seizure activity, and that pilocarpine does not appear to have a global impact on Nova splicing activity."

"Thus perturbing NOVA steady-state levels *in vivo* has relevant physiologic consequences, as haploinsufficiency is sufficient to give rise to spontaneous epilepsy in mice."

"We consistently observed marked shifts of NOVA from the neuronal nucleus to the cytoplasm within 2-4 hours of pilocarpine-induced seizures ... These data suggest that there may in part be a cell biologic mechanism whereby pilocarpine might affect the ability of NOVA to regulate splicing of some targets, but additional experimental follow-up of these observations will be required to fully understand their nature and consequences."

These new data are presented in the following:

• Table 2: Global changes in splicing after pilocarpine seizure

• Table 3: Validation and splicing changes in Nova-regulated targets.

• Figure 6: Nova haploinsufficient mice have spontaneous epilepsy

• Figure 7: Pilocarpine seizures induce a change in Nova subcellular localization.

We note that the sorts of damage the reviewers are concerned about (e.g., Turski et al., as well as a number of subsequent papers) involve neuronal loss happening as a relatively distant event after the induction of pilocarpine seizures. In contrast, we are examining RNA by qRT-PCR 2 hours after seizure.

To be more explicit, Turski et al find evidence of neuronal damage at 5--7 days post pilocarpine seizure. The earliest they noted this was 48 hours. Moreover, they found that pre-treating animals with the muscarinic agonist scopolamine abrogated the severe neuronal damage; we pre-treated animals with 1mg/kg scopolamine 30 minutes prior to pilocarpine injection. Importantly, this pilocarpine protocol is generally used to induce kindling and long-term chronic epilepsy, which, as the reviewers point out, definitely induces long-term neuronal stress including death. On the other hand, the protocol also works as an acute stress---in fact, we used this protocol following discussion and recommendation from one of the world\'s experts in mouse epileptology, Jeff Noebels, who collaborated with us on a recent paper (Ince-Dunn et al., *Neuron*, 2012). Jeff is now included as a co-author on the current manuscript, along with Huidong Wang, given their role in generating and analyzing the more extensive data collection we are including here.

To more directly address the reviewers\' concern, we have now performed immunofluorescence microscopy in the hippocampus, neocortex, and cerebellum, in a series of time points from 1 to 24 hours after pilocarpine-induced seizures (Figure 7). We find no evidence of neuronal loss. Interestingly, however, we noted a redistribution of Nova protein from the nucleus to the cytoplasm, an observation that is both cell-specific (evident in seizing cortical/hippocampus neurons, but not Purkinje neurons, which are not a focus of epileptic seizure) and protein-specific (we see no changes in Map2 staining).

*2. A possible alternative model for the physiological relevance of the authors\' findings is that the Nova-dependent suppression of cryptic exons serves as a mechanism to ensure that specific neuronal transcripts are not spuriously expressed in non-neuronal cells. The authors could readily test this by performing RT-PCR assays on the Nova-regulated transcripts, +/- Upf1 knockdown, in non-neural cells. In this context, it is worth noting related work of Makeyev and co-workers (G&D 26, 1209; 2012), who have identified a class of Ptbp1-dependent retained introns that suppress expression of neural transcripts in non-neural cells*.

The reviewers make the interesting connection between the observations of Nova regulation and Ptbp1 regulation of transcript levels through regulation of PTC exons. The point is well made, specifically the idea that there could be cell-type specific regulation of PTC exons/protein levels within the nervous system in a manner analogous to Ptbp1 regulation of expression levels within different tissues of the body. This issue, including the Makeyev citation, has now been added to the text.

However, we do not believe that it is possible that Nova acts *in vivo* in the manner suggested, as there is no appreciable expression of Nova outside of neurons of the central nervous system (barring trace amounts of RNA detectable by RT-PCR only, whose significance is unclear, but may represent rare truncated transcript isoforms \[unpublished data\]).

In summary, while we could undertake transfections into non-neuronal cells, adding back exogenous Nova to demonstrate Nova-dependent and Upf1-dependent regulation of NMD exons, the experiment would not be as physiologically relevant as the experiments we have done. Specifically, we demonstrate in primary neurons expressing endogenous Nova, or in primary Nova DKO neurons, that the Nova-regulated splicing of NMD exons is required to control Upf1-mediated control of mRNA levels.

*3. The authors utilize a liberal cutoff in their identification of differentially expressed genes from their microarray analysis. A magnitude log2 change of 0.3 corresponds to slightly less than a 1.25 fold ratio change, and given the noise inherent in microarray measurements, it is unlikely that estimated changes in this range will validate at the same rate as those changes estimated to be \>1.5 fold. Accordingly, the authors are requested to use qRT-PCR assays over the range of 229 genes predicted to show expression differences to assess false-positive rates. In this context, the descriptor "widespread" may be overstated*.

We appreciate the reviewers\' point, and have now re-examined our validation data as requested. We present the new data in a revised Table 1. All qRT-PCR was done with 3 biologic replicates (3 animals) and three technical replicates (9 reactions per point). In these data we present analysis of 15 transcripts, with P-values and fold changes analyzed, that are examined using the original liberal cutoff, and, as requested, analysis of 7 new transcripts with much small changes, in the range requested by the reviewers. Perhaps because of the stringency with which we performed both the microarray analysis and the experimental validation, even here the small changes predicted by microarray were consistently seen with the qRT-PCR data, although the quantitative correlation was not as strong overall as for data showing larger changes. In any case, the basic data is now open for readers to review and judge for themselves; we would conclude that the false--positive rate, even for small changes, is relatively low.

To avoid any confusion, we deleted the descriptor "widespread". We also rewrote relevant text, as in the following (which previously referred to "widespread"): "Taken together, these data indicate the extensive use of NOVA in steady-state neurons to inhibit cryptic NMD exons, and, to a lesser degree, mediate inclusion of NMD exons, as a means to maintain or reduce, respectively, the steady-state levels of neuronal transcripts and proteins."

[^1]: Summary of validation data for transcripts showing Nova-dependent change in steady-state mRNA levels. Upper table: validation data for transcripts showing larger fold predicted changes by microarray. Lower table: validation data for transcripts showing small predicted changes by microarray, to illustrate sensitivity of the data. In each table, the first column shows fold change from qRT-PCR, the second column shows fold change from Affymetrix-exon array data, the third column shows the p value and the fourth column shows the name of gene. Data for each gene is derived from three biologic replicates (three animals) and three technical replicates (nine reactions per point); these data are statistically significant (p\<0.001; Student\'s t-test). Genes in bold are cryptic exons confirmed by sequencing (see [Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"} and [Figure 4D](#fig4){ref-type="fig"}). Genes with asterisk are those with robust 3′ UTR clusters (see [Figure 8](#fig8){ref-type="fig"}).

[^2]: Exon junction array results assessing splicing changes in the hippocampus after pilocarpine seizure, compared to sham controls. The total number of alternative exons identified from the brains of pilocarpine treated animals from which RNA was analyzed by genome-wide exon junction arrays is shown. The data in is organized as a function of differing stringency thresholds (as previously described: ΔI, a measure of the inclusion of exons in sham relative to pilocarpine treated animals; ΔI was determined using the ASPIRE algorithm ([@bib81]) and ΔI t-test using ASPIRE2 ([@bib48])). Each data point represents analysis of all results from three pairs of biological replicates. Validated refers to independent qRT-PCR validation (see [Supplementary file 1](#SD2-data){ref-type="supplementary-material"}) of selected transcripts from total.

[^3]: GO (gene ontology) term analysis of transcripts up/down-regulated in WT vs DKO (see [Figure 1A](#fig1){ref-type="fig"}). Data of upper table are derived from top 215 down-regulated transcripts in DKO; (positive value in [Figure 1A](#fig1){ref-type="fig"}). Data of lower table are from top 14 up-regulated transcripts in DKO; (negative value in [Figure 1A](#fig1){ref-type="fig"}). Taken together, two tables suggested that NOVA regulates the levels of many transcripts relating to synaptic transmission ([@bib15]; [@bib29]).
